fluconazole has been researched along with Hyperemia in 3 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Hyperemia: The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to clarify, using functional and biological approaches, the role of epoxyeicosatrienoic acids, nitric oxide (NO)/reactive oxygen species balance, and endothelin-1 in conduit artery endothelial dysfunction during essential hypertension." | 9.16 | Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. ( Bellien, J; Dreano, Y; Gutierrez, L; Iacob, M; Joannides, R; Lucas, D; Mercier, A; Monteil, C; Remy-Jouet, I; Thuillez, C; Vendeville, C, 2012) |
| "We sought to clarify, using functional and biological approaches, the role of epoxyeicosatrienoic acids, nitric oxide (NO)/reactive oxygen species balance, and endothelin-1 in conduit artery endothelial dysfunction during essential hypertension." | 5.16 | Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. ( Bellien, J; Dreano, Y; Gutierrez, L; Iacob, M; Joannides, R; Lucas, D; Mercier, A; Monteil, C; Remy-Jouet, I; Thuillez, C; Vendeville, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, J | 1 |
| Roza, MP | 1 |
| Colli, KG | 1 |
| Dalben, YR | 1 |
| Maifrede, SB | 1 |
| Valiatti, TB | 1 |
| Novo, VM | 1 |
| Cayô, R | 1 |
| Grão-Velloso, TR | 1 |
| Gonçalves, SS | 1 |
| Bellien, J | 1 |
| Iacob, M | 1 |
| Remy-Jouet, I | 1 |
| Lucas, D | 1 |
| Monteil, C | 1 |
| Gutierrez, L | 1 |
| Vendeville, C | 1 |
| Dreano, Y | 1 |
| Mercier, A | 1 |
| Thuillez, C | 1 |
| Joannides, R | 1 |
| Cracowski, JL | 1 |
| Gaillard-Bigot, F | 1 |
| Cracowski, C | 1 |
| Sors, C | 1 |
| Roustit, M | 1 |
| Millet, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)[NCT02584439] | Phase 3 | 30 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for fluconazole and Hyperemia
| Article | Year |
|---|---|
Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension.
Topics: 14-alpha Demethylase Inhibitors; Adult; Eicosanoids; Endothelin-1; Endothelium, Vascular; Enzyme Inh | 2012 |
Involvement of cytochrome epoxygenase metabolites in cutaneous postocclusive hyperemia in humans.
Topics: 8,11,14-Eicosatrienoic Acid; Adult; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; Female; | 2013 |
1 other study available for fluconazole and Hyperemia
| Article | Year |
|---|---|
Candida-associated denture stomatitis: clinical, epidemiological, and microbiological features.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Drug Resistanc | 2023 |